Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.

Women are more likely than men to use rimegepant for migraine prevention. This study looked at how often women and men use this medication. Researchers collected data through an online survey. They focused on adults in the US aged 18 and older. All participants had episodic or chronic migraines. Out of 425 adults surveyed, 152 were using rimegepant for short-term prevention. Of those, 64.5% were women and 35.5% were men. Women often used rimegepant due to doctor recommendations, frequency of attacks, and severity. For women, 69.4% reported doctor recommendations, compared to 48.1% of men. Stress was a common trigger for both genders, affecting 74.5% of women and 59.3% of men. These findings suggest that women may face different challenges in managing migraines compared to men. Understanding these differences can help tailor treatments for better outcomes. Clinical relevance: This study highlights the need for personalized migraine treatment strategies, considering gender differences in medication use and triggers.